Investors on the quest for market-beating returns often employ the strategy of stock picking. Making informed choices in stocks can greatly amplify your wealth.
The closing price of Astrana Health Inc (NASDAQ: ASTH) was $29.1 for the day, up 1.43% from the previous closing price of $28.69. In other words, the price has increased by $1.43 from its previous closing price. On the day, 0.5 million shares were traded. ASTH stock price reached its highest trading level at $29.62 during the session, while it also had its lowest trading level at $28.52.
Ratios:
Our analysis of ASTH’s different ratios will help us gain a deeper understanding of the company. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 4.25 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 11.98. For the most recent quarter (mrq), Quick Ratio is recorded 1.59 and its Current Ratio is at 1.59. In the meantime, Its Debt-to-Equity ratio is 0.58 whereas as Long-Term Debt/Eq ratio is at 0.56.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Barclays on April 01, 2025, initiated with a Equal Weight rating and assigned the stock a target price of $36.
On October 14, 2024, TD Cowen started tracking the stock assigning a Buy rating and target price of $66.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ASTH now has a Market Capitalization of 1343151232 and an Enterprise Value of 1330846080. As of this moment, Astrana’s Price-to-Earnings (P/E) ratio for their current fiscal year is 56.37, and their Forward P/E ratio for the next fiscal year is 14.27. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 1.20. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.60 while its Price-to-Book (P/B) ratio in mrq is 1.87. Its current Enterprise Value per Revenue stands at 0.55 whereas that against EBITDA is 13.415.
Stock Price History:
The Beta on a monthly basis for ASTH is 0.82, which has changed by -0.37526834 over the last 52 weeks, in comparison to a change of 0.18157876 over the same period for the S&P500. Over the past 52 weeks, ASTH has reached a high of $63.20, while it has fallen to a 52-week low of $21.20. The 50-Day Moving Average of the stock is 18.26%, while the 200-Day Moving Average is calculated to be -11.32%.
Shares Statistics:
ASTH traded an average of 341.63K shares per day over the past three months and 637800 shares per day over the past ten days. A total of 49.14M shares are outstanding, with a floating share count of 37.13M. Insiders hold about 25.63% of the company’s shares, while institutions hold 51.98% stake in the company. Shares short for ASTH as of 1753920000 were 1606105 with a Short Ratio of 4.70, compared to 1751241600 on 1432014. Therefore, it implies a Short% of Shares Outstanding of 1606105 and a Short% of Float of 5.56.
Earnings Estimates
A comprehensive evaluation of Astrana Health Inc (ASTH) is underway, with the input of 2.0 analysts contributing to its current rating.The consensus estimate for the next quarter is $0.6, with high estimates of $0.6 and low estimates of $0.6.
Analysts are recommending an EPS of between $2.27 and $2.23 for the fiscal current year, implying an average EPS of $2.25. EPS for the following year is $2.36, with 2.0 analysts recommending between $2.64 and $2.08.
Revenue Estimates
It is expected that $90B in revenue will be generated in the current quarter, according to 9 analysts. It ranges from a high estimate of $966.7M to a low estimate of $932M. As of the current estimate, Astrana Health Inc’s year-ago sales were $478.71MFor the next quarter, 9 analysts are estimating revenue of $984.01M. There is a high estimate of $1.02B for the next quarter, whereas the lowest estimate is $962.26M.
A total of 10 analysts have provided revenue estimates for ASTH’s current fiscal year. The highest revenue estimate was $3.26B, while the lowest revenue estimate was $3.18B, resulting in an average revenue estimate of $3.21B. In the same quarter a year ago, actual revenue was $2.03BBased on 10 analysts’ estimates, the company’s revenue will be $4.07B in the next fiscal year. The high estimate is $4.23B and the low estimate is $3.81B.
